Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1231630 | 0.95 | LMNA (0.38) | SLC22A6TSHRLMNAALDH1A1NFKB1 | |
| SCHEMBL9866159 | 0.93 | TSHR (0.40) | SLC22A6TSHRLMNAALDH1A1NFKB1 | |
| SCHEMBL28067146 | 0.93 | TSHR (0.40) | SLC22A6TSHRLMNAALDH1A1NFKB1 | |
| SCHEMBL9866476 | 0.93 | TSHR (0.40) | SLC22A6TSHRLMNAALDH1A1NFKB1 | |
| SCHEMBL3903619 | 0.89 | TSHR (0.36) | SLC22A6TSHRALDH1A1APEX1 | |
| SCHEMBL3176102 | 0.86 | MAOA (0.31) | CYP1A2CYP3A4CYP2C19MEN1KMT2A | |
| SCHEMBL25347728 | 0.81 | BLM (0.34) | PMP22HSD17B10BLM | |
| SCHEMBL1467658 | 0.79 | TDP1 (0.31) | TDP1 | |
| SCHEMBL6937746 | 0.77 | — | — | |
| SCHEMBL959395 | 0.77 | TDP1 (0.31) | TSHRLMNAPMP22CYP2C19BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105384739-B | Pyrazolo [3,4-c ] pyridine derivatives | 石药集团中奇制药技术（石家庄）有限公司 | 2020-03-20 | — | — | CN | disclosed |
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA (SE) | 2009-10-29 | — | — | US | disclosed |
| EP-0948495-B1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | AMGEN INC (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6605634-B2 | Tumor necrosis factor alpha and interleukin-1 (IL-1) mediated diseases; pain, diabetes; cyclooxygenase inhibition | AMGEN, INC. | 2003-08-12 | — | — | US | disclosed |
| US-20030096819-A1 | Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents | AMGEN INC. | 2003-05-22 | — | — | US | disclosed |
| US-6440973-B1 | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents | AMGEN INC. | 2002-08-27 | — | — | US | disclosed |
| EP-0714299-B1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6180643-B1 | ANTAGONIST OF INTERLEUKINS, TUMOR NECROSIS FACTOR | AMGEN INC. | 2001-01-30 | — | — | US | disclosed |
| EP-0948495-A1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | Amgen Inc., (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998022457-A9 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022457-A1 | ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS | AMGEN INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| US-5665719-A | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0714299-A4 | — | — | 1996-07-10 | — | — | EP | disclosed |
| EP-0714299-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995002405-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0300189-B1 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-11-02 | — | — | EP | disclosed |
| US-5223489-A | Treatment of ypertension and heart failure | UJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5142048-A | Enzyme inhibitor; carbamoyl group-containing acids | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| US-4921855-A | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0300189-A2 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096819-A1 | Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents | TNF, IL1A, IL6 | SLC22A6 4197/4885TSHR 3615/4885LMNA 4479/4885 |
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | TYMP, DPYD, TYMS | SLC22A6 3446/4885TSHR 1756/4885LMNA 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.